As a novel potassium-competitive acid blocker, VONOZOPRAN FUMARATE may provide reversible acid suppression by preventing K+ from binding to gastric H+/K+-ATPase. It has been clinically used for the short-term treatment of gastroesophageal reflux disease (GERD), peptic ulcer disease and Helicobacter pylori (H. pylori) infection.

Products still subject to third-party patent protection might be available solely for R&D purposes.

MOSAPRIDE CITRATE is a gastroprokinetic agent that acts as a selective 5HT4 agonist. The major active metabolite of mosapride, known as M1, additionally acts as a 5HT3 antagonist, which accelerates gastric emptying throughout the whole of the gastrointestinal tract in humans.

Products still subject to third-party patent protection might be available solely for R&D purposes.

RABEPRAZOLE SODIUM HYDRATE is a medication that decreases stomach acid. it is used to treat peptic ulcer disease, gastroesophageal reflux disease, and excess stomach acid production.

Products still subject to third-party patent protection might be available solely for R&D purposes.

PRANLUKAST HYDRATE is a cysteinyl leukotriene receptor-1 antagonist. It is widely used in Japan.

Products still subject to third-party patent protection might be available solely for R&D purposes.